OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.
This opinion paper seeks to introduce a disruptive model to accelerate product and process development in the biopharmaceutical industry, especially for vaccines. This model is based on the minimum valuable product and process (MVaP&P), a new concept that allows for adaptation and acceleration, which would enable agility in the way biopharmaceuticals are developed. This article discusses how the MVaP&P approach would make it is possible to discipline and structure biopharmaceutical development to achieve a phase-appropriate and strategy-aligned product in the fastest time possible.
Submitted: May 12, 2022
Article accepted: June 28, 2022
Matthew Sanders* is vice-president, head of Global Drug Substance; Roland Mainil is director, Technical Development Lead; and Wael Chahim* is associate director, Development Unit Head; all at GSK, Rixensart, Belgium.
*Both authors contributed equally to this paper.
Vol. 35, No. 10
When referring to this article, please cite it as M. Sanders, R. Mainil, and W. Chahim, “Introducing a New Concept for Value-Driven Acceleration in Biopharma Development,” BioPharm International 35 (10) 34–41 (2022).